Universität zu Köln

2021

Eichenauer, D. A., Kreissl, S., Buehnen, I., Baues, C., Kobe, C., van Heek, L., Goergen, H., Fuchs, M., Hartmann, S., von Tresckow, B., Engert, A. and Borchmann, P. (2021). PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. Ann. Oncol., 32 (6). S. 807 - 811. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2020

Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Eichenauer, D. A., Kreissl, S., Buehnen, I., Goergen, H., Hartmann, S., Fuchs, M., von Tresckow, B., Engert, A. and Borchmann, P. (2020). PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 87 - 89. BASEL: KARGER. ISSN 2296-5262

Gillessen, S., Pluetschow, A., Fuchs, M., Markova, J., Greil, R., Topp, M., Meissner, J., Zijlstra, J., Eichenauer, D., Broeckelmann, P., Diehl, V., Borchmann, P., Engert, A. and von Tresckow, B. (2020). Dose-Intensification in early unfavorable Hodgkin Lymphoma: Long-Term Follow up of the randomized German Hodgkin Study Group (GHSG) HD14 trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 88 - 90. BASEL: KARGER. ISSN 2296-5262

Goereci, Y., Schweitzer, F., Wellstein, A., Silling, S., Borchmann, S., von Tresckow, B., Adams, O., Martin, R., Schlamann, M., Schroeter, M., Fink, G. R., Wattjes, M. P. and Warnke, C. (2020). Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome. Eur. J. Neurol., 27 (11). S. 2375 - 2378. HOBOKEN: WILEY. ISSN 1468-1331

Momotow, J., Sasse, S., Pluetschow, A., Huettmann, A., Basara, N., Koenecke, C., Martin, S., Bentz, M., Grosse-Thie, C., Thorspecken, S., de Wit, M., Kobe, C., Dietlein, M., von Tresckow, B., Fuchs, M., Borchmann, P. and Engert, A. (2020). AFM13 in patients with relapsed or refractory Hodgkin Lymphoma: Final results of an open-label, randomized, multicenter phase II trial. Oncol. Res. Treat., 43 (SUPPL 4). S. 89 - 90. BASEL: KARGER. ISSN 2296-5262

2018

Borchmann, S., Goergen, H., Sasse, S., Kreissl, S., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Diehl, V. and Engert, A. (2018). Pretreatment vitamin D deficiency is associated with lower progression free and overall survival in prospectively treated Hodgkin lymphoma. Oncol. Res. Treat., 41. S. 273 - 275. BASEL: KARGER. ISSN 2296-5262

Jakob, T., Follmann, M., Borchmann, P., Baues, C., Sasse, S., Broeckelmann, P. J., Kreissl, S., Eichenauer, D., von Tresckow, B., Buerkle, C., Engert, A. and Skoetz, N. (2018). Guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients. Oncol. Res. Treat., 41. S. 17 - 18. BASEL: KARGER. ISSN 2296-5262

von Tresckow, B. (2018). Treatment of relapse. Oncol. Res. Treat., 41. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262

2017

Borchmann, S., Hude, I., Sasse, S., Broeckelmann, P., von Tresckow, B., Momotow, J. and Engert, A. (2017). Leukocyte and eosinophil count at baseline predict outcome in relapsed or refractory classical Hodgkin lymphoma patients treated with immune checkpoint inhibitors. Oncol. Res. Treat., 40. S. 142 - 144. BASEL: KARGER. ISSN 2296-5262

Broeckelmann, P. J., Mueller, H., Casasnovas, O., Hutchings, M., von Tresckow, B., Jurgens, M., McCall, S. J., Morschhauser, F., Fuchs, M., Borchmann, P., Moskowitz, C. H. and Engert, A. (2017). Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann. Oncol., 28 (6). S. 1352 - 1359. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Broeckelmann, P. J., Mueller, H., Kuecueksarioglan, E., Engert, A. and von Tresckow, B. (2017). DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 146 - 147. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Borchmann, P. and Engert, A. (2017). Long-term outcome of patients with early-stage nodular lymphocyte-predominant hodgkin lymphoma (NLPHL) treated within the randomized HD7, HD10 and HD13 trials: An analysis from the German Hodgkin Study Group (GHSG). Oncol. Res. Treat., 40. S. 142 - 143. BASEL: KARGER. ISSN 2296-5262

Eichenauer, D. A., Pluetschow, A., Fuchs, M., von Tresckow, B., Diehl, V., Borchmann, P. and Engert, A. (2017). LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP. Haematologica, 102. S. 82 - 83. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hude, I., Sasse, S., Broeckelmann, P. J., von Tresckow, B., Momotow, J., Engert, A. and Borchmann, S. (2017). BASELINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION. Haematologica, 102. S. 460 - 461. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2016

Eichenauer, D. A., Goergen, H., Pluetschow, A., Wongso, D., Behringer, K., Kreissl, S., Thielen, I., Halbsguth, T., Broeckelmann, P. J., Fuchs, M., Boell, B., von Tresckow, B., Borchmann, P. and Engert, A. (2016). Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia, 30 (6). S. 1425 - 1429. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY. Haematologica, 101. S. 44 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M. A., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

von Tresckow, B., Kreissl, S., Haverkamp, H., Sasse, S., Diehl, V., Engert, A. and Borchmann, P. (2016). BEACOPP-ESCALATED FOLLOWED BY RADIOTHERAPY OF INITIAL BULK OR RESIDUAL DISEASE IN ADVANCED-STAGE HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GHSG HD9 AND HD12 TRIALS. Haematologica, 101. S. 18 - 19. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2015

Boell, B., Pluetschow, A., Eichenauer, D., von Tresckow, B., Atta, J., Pfreundschuh, M., Michaela, F. B., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2015). GERMAN HODGKIN STUDY GROUP PHASE I TRIAL OF DOXORUBICIN, VINBLASTINE, DACARBAZINE, AND LENALIDOMIDE (AVD-REV) FOR ELDERLY HODGKIN LYMPHOMA PATIENTS-FINAL ANALYSIS. Haematologica, 100. S. 322 - 323. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2014

Behringer, K., Goergen, H., Borchmann, P., Diehl, V., Fuchs, M., Lohri, A., Hitz, F., Zijlstra, J. M., Greil, R., Markova, J., Topp, M. S., Soekler, M., Mathas, S., Meissner, J., von Tresckow, B., Boell, B. and Engert, A. (2014). IMPACT OF BLEOMYCIN AND DACARBAZINE WITHIN THE ABVD REGIMEN IN THE TREATMENT OF EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: FINAL RESULTS OF THE GHSG HD13 TRIAL. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Boell, B., Pluetschow, A., Eichenauer, D. A., Thielen, I, von Tresckow, B., Atta, J., Pfreundschuh, M., Feuring-Buske, M., Vogelhuber, M., Soekler, M., Fuchs, M., Engert, A. and Borchmann, P. (2014). German Hodgkin Study Group Phase I trial of Doxorubicin, Vinblastine, Dacarbazine, and Lenalidomide (AVD-Rev) for elderly Hodgkin Lymphoma patients. Oncol. Res. Treat., 37. S. 12 - 13. BASEL: KARGER. ISSN 2296-5262

Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. -G, Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). Final analysis of a randomized phase II trial with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma -PVAG-14 pilot-. Oncol. Res. Treat., 37. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262

Fuchs, M., Wongso, D., Pluetschow, A., Feuring-Buske, M., Hertenstein, B., Hoeffkes, H. G., Vogelhuber, M., von Tresckow, B., Biersack, H., Link, H., Topp, M. S., Fischer, N., Bredenfeld, H., Sasse, S., Behringer, K., Boell, B., Borchmann, P. and Engert, A. (2014). FINAL ANALYSIS OF A RANDOMIZED PHASE II STUDY WITH PREDNISONE, VINBLASTINE, DOXORUBICIN, AND GEMCITABINE IN PATIENTS WITH EARLY UNFAVORABLE HODGKIN LYMPHOMA -PVAG-14 PILOT-. Haematologica, 99. S. 497 - 498. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Oki, Y., Buglio, D., Zhang, J., Ying, Y., Zhou, S., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P. B., Shen, A., von Tresckow, B. and Younes, A. (2014). Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J., 4. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385

Rancea, M., von Tresckow, B., Monsef, I, Engert, A. and Skoetz, N. (2014). The role of high-dose chemotherapy followed by autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma: a systematic review with meta-analysis. Oncol. Res. Treat., 37. S. 147 - 148. BASEL: KARGER. ISSN 2296-5262

Sickinger, M. T., von Tresckow, B., Kobe, C., Engert, A., Borchmann, P. and Skoetz, N. (2014). PET-ADAPTED TREATMENT MODIFICATION IN EARLY STAGE HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Haematologica, 99. S. 399 - 400. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

von Tresckow, B. and Engert, A. (2014). Brentuximab vedotin. A new targeted approach for the treatment of relapsed or refractory Hodgkin's lymphoma patients. Onkologe, 20 (5). S. 464 - 470. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

von Tresckow, B., Goebeler, M. E., Sayehli, C., Gundermann, S., Eichenauer, D., Aulitzky, W., Bacchus, L., Igel, S., Schwab, M., Sasse, S., Hauns, B., Mais, A., Hentsch, B., Kohlhof, H., Krauss, R., Krauss, B., Baumgartner, R., Vitt, D. and Engert, A. (2014). FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY). Haematologica, 99. S. 711 - 712. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2013

Klimm, B., Goergen, H., Fuchs, M., von Tresckow, B., Boell, B., Meissner, J., Glunz, A., Diehl, V., Eich, H. T., Engert, A. and Borchmann, P. (2013). Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions. Ann. Oncol., 24 (12). S. 3070 - 3077. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041